Altimmune
ALT
169 hedge funds and large institutions have $243M invested in Altimmune in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 60 increasing their positions, 46 reducing their positions, and 25 closing their positions.
39% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $8.53M
30% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 173 → 169 (-4)
4.18% less ownership
Funds ownership: 59.83% → 55.64% (-4.2%)
14% less capital invested
Capital invested by funds: $282M → $243M (-$39.1M)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$4.42M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.89M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$1.79M |
| 4 |
Jane Street
New York
|
+$1.67M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.69M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$3.92M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.36M |
| 4 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
-$3.24M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.92M |
ALT Hedge Fund Activity: Q3 2024 in Review
169 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q3 2024, worth a combined $243M — down 14% from $282M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ALT and 21 opened new positions — a net loss of 4 holders — while 46 trimmed existing stakes and 60 added.
The largest buyer was Ameriprise, adding an estimated $4.42M. The largest seller was Susquehanna International Group, cutting an estimated $8.69M.
- 169 institutional investors held Altimmune (ALT) as of Q3 2024, down from 173 in Q2 2024.
- Funds reported $243M of Altimmune stock for Q3 2024, down 14% quarter-over-quarter.
- 21 funds opened new Altimmune positions in Q3 2024 and 25 closed out, a net change of -4 holders.
- The largest Altimmune buyer in Q3 2024 was Ameriprise, an estimated $4.42M added.
- The largest Altimmune seller in Q3 2024 was Susquehanna International Group, an estimated $8.69M sold.
Based on aggregated 13F filings for Q3 2024.